Heron Therapeutics Inc vs Advanced Drainage Systems Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Advanced Drainage Systems Inc trades at $125.56 (market cap $9.51B). The key difference: Advanced Drainage Systems Inc is far larger — about 128.4× Heron Therapeutics Inc's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Advanced Drainage Systems Inc for 43 Days on average.
| HRTX | WMS | |
|---|---|---|
Market Cap | $74.04M | $9.51B |
Volume | 3,668,095 | 771,064 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $175.38 |
52-Week Low | $0.27 | $125.33 |
Typical Hold Time | 35 Days | 43 Days |
Enterprise Value | $180.78M | $11.11B |
Dividend Yield | — | 0.63% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Advanced Drainage Systems (WMS) trades at $126.21, down 2.97% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin. Recent news includes the release of its 2026 Sustainability Report and a quarterly dividend declaration.
The outlook is mixed; analyst consensus targets $188.70, implying significant upside, but near-term technical pressure and a projected net cash outflow in 2026 present risks. Investment appeal hinges on execution of growth initiatives and margin stability against macroeconomic and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →